Trends · Daily since 18:00
Signal, by category.
Pivot the desk by domain — clinical AI, longevity, neurotech, policy, Portugal. Grouped by day, with the 18:00 daily read at the top of each.
ShowHide briefing index
BioPharma Dive
Jasper Therapeutics Acquired by Kira Pharmaceuticals, Secures Mirador Licensing Deal
"While the M&A offers a lifeline, the necessity for a concurrent licensing deal with Mirador suggests ongoing R&D challenges or an underperforming pipeline at Jasper, impacting unit economics for the combined entity. This reflects the intense capital demands and inherent risks within niche biopharma."
Read source →
MedCity News
Juno Bio Secures $3.8M for Vaginal Microbiome Diagnostics
"While the funding signifies investor confidence, the real traction for Juno Bio will depend on demonstrating superior clinical utility and clear reimbursement pathways for its diagnostic tools, particularly given existing women's health diagnostic options."
Read source →
MedCity News
GSK’s $2B Chronic Cough Drug, Camlipixant, Fails Phase 3
"This preclinical failure underscores the high attrition rates even for well-funded programs, illustrating that capital deployment does not guarantee clinical efficacy or regulatory approval; the mechanism of action did not translate to desired patient outcomes."
Read source →
ShowHide briefing index
- 1.AI in healthcare: The 'Bot vs. Bot' dynamic is driving up costs
- 2.GSK Pulls Camlipixant: $2B Cough Drug Fails Phase 3
- 3.MDCalc Launches Clinical Calculator Quality Ratings, Aims for Wider Physician Adoption
- 4.Antwerp's Sightera Bio raises €3M pre-Seed for patient-derived AI drug discovery
- 5.Generative AI Designs DNA Origami
- 6.Neko raises $700m Series C: ‘We now have 100k members and are profitable at clinic level’
- 7.US House Committee Unanimously Approves Medicare Advantage Prior Auth Bill
- 8.CMS Proposes Ban on Third-Party Remote Patient Monitoring Reimbursement Amid Fraud Concerns
MedCity News
AI in healthcare: The 'Bot vs. Bot' dynamic is driving up costs
"The issue is not just friction between AI bots, but a fundamental lack of trust in data integrity and shared incentives across siloed healthcare systems. Mandated interoperability standards, not just voluntary data sharing, are required to address the unit economics of this administrative burden."
Read source →
BioPharma Dive
GSK Pulls Camlipixant: $2B Cough Drug Fails Phase 3
"This failure underscores the high attrition rate in drug development, where compelling preclinical rationale and significant investment often fall short against the rigorous demands of Phase 3 clinical efficacy and safety endpoints, regardless of market size."
Read source →
STAT News – Health Tech
MDCalc Launches Clinical Calculator Quality Ratings, Aims for Wider Physician Adoption
"While a quality-rating system for clinical calculators is a net positive for adoption and trust, its impact hinges on the rigor of the underlying methodology and the transparency of its evidence-based scoring criteria, not just the mere existence of a rating."
Read source →
EU-Startups
Antwerp's Sightera Bio raises €3M pre-Seed for patient-derived AI drug discovery
"Another early-stage AI drug discovery raise. The clinical utility of patient-derived models in early discovery remains a throughput challenge until specific validation pathways for synthetic data generation demonstrate direct clinical translatability, not just in-vitro correlation."
Read source →
IEEE Spectrum – Biomedical
Generative AI Designs DNA Origami
"While novel for nanoscale structural engineering, the clinical utility for this specific DNA origami application remains distant, lacking a direct biological mechanism for therapeutic or diagnostic impact."
Read source →
Sifted – Healthtech
Neko raises $700m Series C: ‘We now have 100k members and are profitable at clinic level’
"The clinic-level profitability claim for Neko is notable but must be scrutinized against overall company burn rate; significant funding rounds don't always translate to sustainable unit economics for expansion."
Read source →
MedCity News
US House Committee Unanimously Approves Medicare Advantage Prior Auth Bill
"Prior authorization, rooted in payer cost-control incentives, stifles provider autonomy; this unanimous vote suggests a bipartisan recognition of the adverse patient and system impacts, though implementation challenges remain for any regulator."
Read source →
MedCity News
CMS Proposes Ban on Third-Party Remote Patient Monitoring Reimbursement Amid Fraud Concerns
"The move is a blunt, yet predictable, regulatory response to rampant billing fraud, signaling CMS's intent to centralize accountability for RPM services directly with physician practices and dismantle revenue stream arbitrages, rather than refine oversight of third-party operators. This will shrink the RPM market to hospital-integrated offerings or those direct-to-consumer not relying on CMS reimb"
Read source →
Adjacent
The people building all this show up in Lisbon & Porto — see the programme or reserve a seat.